Artal Group S.A. Lexicon Pharmaceuticals, Inc. Transaction History
Artal Group S.A.
- $62.6 Million
- Q1 2025
A detailed history of Artal Group S.A. transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Artal Group S.A. holds 136,180,481 shares of LXRX stock, worth $154 Million. This represents 100.0% of its overall portfolio holdings.
Number of Shares
136,180,481
Previous 136,180,481
-0.0%
Holding current value
$154 Million
Previous $101 Million
37.84%
% of portfolio
100.0%
Previous 100.0%
Shares
8 transactions
Others Institutions Holding LXRX
# of Institutions
136Shares Held
199MCall Options Held
310KPut Options Held
77.3K-
Black Rock Inc. New York, NY9.89MShares$11.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.56MShares$10.8 Million0.0% of portfolio
-
Schonfeld Strategic Advisors LLC New York, NY8.21MShares$9.28 Million0.03% of portfolio
-
Geode Capital Management, LLC Boston, MA3.69MShares$4.17 Million0.0% of portfolio
-
Siren, L.L.C. New York, NY3.52MShares$3.97 Million0.09% of portfolio
About LEXICON PHARMACEUTICALS, INC.
- Ticker LXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 188,726,000
- Market Cap $213M
- Description
- Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...